Guardat en:
| Autor principal: | |
|---|---|
| Format: | Recurso digital |
| Idioma: | |
| Publicat: |
Zenodo
2025
|
| Matèries: | |
| Accés en línia: | https://doi.org/10.5281/zenodo.17552140 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
Taula de continguts:
- <p><span>Mucoadhesive drug delivery systems (MDDS) represent a novel approach to improve therapeutic effectiveness by utilizing the adhesive interaction between polymers and the mucosal surface. These systems enhance drug residence time, increase absorption, and bypass hepatic first-pass metabolism, thereby improving the bioavailability of drugs with poor oral absorption. MDDS have been developed for multiple routes, including oral, buccal, nasal, vaginal, rectal, ocular, and gastrointestinal delivery, using dosage forms such as tablets, films, gels, microspheres, nanoparticles, and sprays. The mechanism of mucoadhesion is explained through various theories electronic, adsorption, wetting, diffusion, and fracture and is influenced by polymer type, hydration, pH, and mucosal physiology. Both natural and synthetic polymers, including chitosan, Carbopol, and cellulose derivatives, are widely used to achieve desirable adhesion and controlled release. Evaluation parameters involve mechanical strength, bioadhesive force, swelling studies, in vitro dissolution, permeability, and in vivo pharmacokinetic assessments. Despite certain limitations, such as dose restrictions and mucosal variability, continuous advances in polymer science, nanotechnology, and smart delivery carriers are expanding the clinical potential of MDDS. With increasing patient compliance and several marketed formulations, mucoadhesive systems continue to be a promising and rapidly growing area in pharmaceutical research. </span></p>